VolitionRx Limited (NYSE:VNRX) Insider Jacob Vincent Micallef Buys 50,000 Shares

VolitionRx Limited (NYSE:VNRX) insider Jacob Vincent Micallef bought 50,000 shares of the firm’s stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $0.43 per share, with a total value of $21,500.00. Following the completion of the transaction, the insider now owns 426,033 shares in the company, valued at $183,194.19. This represents a 13.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

VolitionRx Price Performance

VNRX stock traded down $0.01 during midday trading on Monday, hitting $0.42. 468,938 shares of the stock traded hands, compared to its average volume of 180,132. The stock’s fifty day simple moving average is $0.51 and its 200-day simple moving average is $0.59. The firm has a market cap of $42.33 million, a P/E ratio of -1.17 and a beta of 1.00. VolitionRx Limited has a 1-year low of $0.40 and a 1-year high of $0.90.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VNRX. Northern Trust Corp raised its position in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Two Sigma Securities LLC purchased a new stake in VolitionRx in the fourth quarter valued at $29,000. Millennium Management LLC purchased a new stake in VolitionRx in the fourth quarter valued at $36,000. Finally, Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

Analyst Upgrades and Downgrades

VNRX has been the topic of a number of research reports. HC Wainwright initiated coverage on VolitionRx in a report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price objective on the stock. StockNews.com initiated coverage on VolitionRx in a report on Thursday. They issued a “sell” rating on the stock. Finally, D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday, April 30th.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.